Literature DB >> 30350904

Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas.

M Théaudin1, P Lozeron2, V Algalarrondo3,4, C Lacroix3,5, C Cauquil3,6, C Labeyrie3,6, M S Slama3,4, C Adam3,5, A Guiochon-Mantel3,7, D Adams3,6.   

Abstract

BACKGROUND AND
PURPOSE: The aim is to describe an uncommon phenotype of hereditary ATTR neuropathy with upper limb onset.
METHODS: The French TTR Familial Amyloid Polyneuropathy database was used for a retrospective evaluation of 32 consecutive patients with upper limb onset of the neuropathy (study group) and they were compared to 31 Portuguese early-onset patients and 99 late-onset patients without upper limb onset.
RESULTS: Initial upper limb symptoms were mostly sensory. Lower limb symptoms began 2.3 ± 3 years after upper limb symptoms. Twenty-four (75%) patients were initially misdiagnosed, with 15 different diagnoses. More patients in the study group had a Neuropathy Impairment Score upper limb/lower limb ratio > 1 compared to the late-onset patient group. The study group had significantly more pronounced axonal loss in the median and ulnar motor nerves and the ulnar sensory and sural nerves. On radial nerve biopsies (n = 11), epineurial vessels were abnormal in six cases, including amyloid deposits in vessel walls (3/11), with vessel occlusion in two cases.
CONCLUSION: Upper limb onset of hereditary ATTR neuropathy is not rare in non-endemic areas. It is important to propose early TTR sequencing of patients with idiopathic upper limb neuropathies, as specific management and treatment are required.
© 2018 EAN.

Entities:  

Keywords:  autonomic diseases; hATTR amyloidosis; peripheral neuropathy

Mesh:

Year:  2018        PMID: 30350904     DOI: 10.1111/ene.13845

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.

Authors:  Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-03-07       Impact factor: 13.654

2.  The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis.

Authors:  Montserrat Vera-Llonch; Sheila R Reddy; Eunice Chang; Marian H Tarbox; Michael Pollock
Journal:  Orphanet J Rare Dis       Date:  2021-01-11       Impact factor: 4.123

3.  Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M.

Authors:  Hsueh-Wen Hsueh; Chi-Chao Chao; Koping Chang; Yung-Ming Jeng; Masahisa Katsuno; Haruki Koike; Sung-Tsang Hsieh
Journal:  Front Aging Neurosci       Date:  2022-01-26       Impact factor: 5.750

Review 4.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

Review 5.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

Authors:  Marco Luigetti; Angela Romano; Andrea Di Paolantonio; Giulia Bisogni; Mario Sabatelli
Journal:  Ther Clin Risk Manag       Date:  2020-02-21       Impact factor: 2.423

6.  Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.

Authors:  Morie Gertz; David Adams; Yukio Ando; João Melo Beirão; Sabahat Bokhari; Teresa Coelho; Raymond L Comenzo; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Julian D Gillmore; Martha Grogan; Philip N Hawkins; Isabelle Lousada; Arnt V Kristen; Frederick L Ruberg; Ole B Suhr; Mathew S Maurer; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Ronald Witteles; Giampaolo Merlini
Journal:  BMC Fam Pract       Date:  2020-09-23       Impact factor: 2.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.